+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 105 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating BG-C137, an antibody-drug conjugate targeting FGFR2b, in people with advanced solid tumors. This study aims to assess the safety, tolerability, how the drug moves and acts in the body, and early antitumor effects. It is a phase 1ab trial involving participants with tumors expressing FGFR2b or FGFR2 gene amplification who have received prior cancer treatments. The study is sponsored by BeOne Medicines and includes two main phases dose escalation and dose expansion. The trial has three parts Phase 1a evaluates increasing doses of BG-C137 alone and then in combination with other anticancer agents to establish safe dose levels. Phase 1b further explores the recommended dose in selected patient groups. BG-C137 and anticancer agents are given intravenously or orally depending on the treatment. Participants undergo dose escalation, safety expansions, and dose confirmations to determine the best dosing for further study. Participants will be monitored regularly for side effects and response to treatment for up to about two years. Assessments include measuring adverse events, drug levels in the blood, tumor response, and immune reactions to the drug. Safety follow-up visits occur after treatment ends. Researchers will measure outcomes such as maximum tolerated dose, overall response rate, disease control, and progression-free survival. The trial involves frequent visits for treatment and assessments throughout the study period.

Age: 18Years +All GendersPhase 1
52 locations
I

Actively Recruiting

Researchers are evaluating the safety, tolerability, pharmacokinetics, and early antitumor activity of the drug BG-C0979 alone or combined with tislelizumab in adults with certain advanced solid tumors. This first-in-human study includes Phase 1a, focusing on dose escalation and safety expansion, and Phase 1b, which involves dose optimization and expansion. The study is sponsored by BeOne Medicines and aims to find safe and effective doses for future research. Participants will receive BG-C0979 through intravenous infusion. In Phase 1a, doses are gradually increased to find safe levels, followed by safety expansion at selected doses. In Phase 1b, participants receive optimized doses of BG-C0979 alone or in combination with tislelizumab for selected tumor types. The study includes multiple treatment groups, each with specific dosing plans and evaluation periods lasting up to approximately 24 months. During the study, participants will undergo regular assessments including imaging to measure tumor response, laboratory tests, and monitoring of side effects. Researchers will track drug levels in blood and evaluate measures like overall response rate, duration of response, disease control rate, and progression-free survival. This comprehensive monitoring will continue for up to two years to evaluate safety and preliminary effectiveness of the treatments.

Age: 18Years +All GendersPhase 1
18 locations
L

Actively Recruiting

Primary immune thrombocytopenia ITP is a condition where the immune system mistakenly destroys platelets, leading to a low platelet count that increases the risk of bruising and bleeding. This Phase 3 study aims to evaluate the long-term safety, tolerability, and effectiveness of mezagitamab, a subcutaneous injection, in adults with chronic primary ITP. It also studies how the body processes mezagitamab over an extended period. Eligible participants who completed previous mezagitamab studies TAK-079-3002 or TAK-079-1004 may join this continuation trial. Those from TAK-079-1004 must have shown a platelet response previously. Participants receive mezagitamab treatment on demand based on defined dosing criteria and the clinical judgment of the investigator, with treatment courses possibly repeated as needed. During the trial, participants visit the study clinic multiple times for assessments including monitoring treatment-emergent adverse events, platelet response duration, use of rescue therapy, and drug levels in the blood. The study lasts up to about 108 weeks, with evaluations of safety, effectiveness, immunogenicity, and dosing patterns throughout this period.

Age: 18Years +All GendersPhase 3
118 locations
P

Actively Recruiting

Researchers are evaluating the drug INCA033989 compared with the best available therapy in participants who have essential thrombocythemia ET with a CALR mutation and who have previously been treated with cytoreductive therapy. This phase 3, randomized, open-label study aims to assess the treatment effects in this specific group of patients with high-risk ET. Participants will receive either INCA033989 administered intravenously according to the study protocol or the best available therapy chosen by the investigator. The study treatments are given in parallel groups and will be monitored to compare responses and safety. The main study period includes treatment and observation up to at least 48 weeks, with follow-up for adverse events for 60 days after the last dose. During the study, participants will attend regular visits for assessments including clinical and hematologic responses, mutation frequency measurements, symptom assessments, and fatigue evaluations. Researchers will monitor treatment-emergent adverse events and measure durable responses at weeks 24 and 48. The total study duration extends until November 2030, with ongoing monitoring of patient health and responses throughout the treatment and follow-up periods.

Age: 18Years +All GendersPhase 3
193 locations
P

Actively Recruiting

This trial focuses on elderly patients aged 80 years or older, or those 75 years and older who are considered frail, with untreated diffuse large B-cell lymphoma DLBCL and related lymphoma subtypes. The study is a phase III, randomized, open-label, multicenter trial conducted in several countries including Sweden, Norway, Finland, Denmark, Italy, Australia, and New Zealand. It aims to compare the standard chemotherapy regimen R-miniCHOP with an experimental treatment R-pola-miniCHP, where vincristine is replaced by polatuzumab vedotin, to assess differences in outcomes for this patient population. Participants will be randomly assigned to one of two treatment groups. One group will receive R-mini-CHOP consisting of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone over six 21-day cycles. The other group will receive R-pola-mini-CHP, which includes rituximab, cyclophosphamide, doxorubicin, prednisone, and polatuzumab vedotin instead of vincristine, also given over six 21-day cycles. Both treatments last approximately 18 weeks. The study includes a screening period lasting up to 4 weeks before treatment begins. During the study, participants will be followed for up to 36 months after completing treatment to monitor progression-free survival over two years. Researchers will evaluate disease progression and safety outcomes through regular assessments during and after the treatment period. Participants will provide informed consent and undergo evaluations including health status and disease measurements to ensure eligibility and monitor treatment effects throughout the trial.

Age: 75Years +All GendersPhase 3
69 locations
C

Actively Recruiting

Researchers are evaluating how the study medicine CagriSema helps adults living with obesity, with or without type 2 diabetes, lose weight. This clinical trial compares two different doses of CagriSema with semaglutide, a medicine already prescribed for weight loss. The study aims to understand the safety and effectiveness of CagriSema in reducing body weight over time. Participants are randomly assigned to receive one of three treatments CagriSema at dose level 1, CagriSema at dose level 2, or semaglutide. Each treatment is given once weekly as a subcutaneous injection over a 72-week period. The study lasts about 83 weeks in total to include all treatment and follow-up time. During the study, participants will have regular visits for assessments including body weight, body mass index, waist circumference, cholesterol levels, and blood sugar control. Questionnaires on physical function and quality of life will also be completed. Researchers will track any side effects and serious adverse events throughout the study and after treatment ends, monitoring safety for up to 80 weeks.

Age: 18Years +All GendersPhase 3
303 locations
S

Actively Recruiting

Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.

Age: 18Years +All GendersPhase 3
838 locations
C

Actively Recruiting

Researchers are evaluating AZD0120, a dual-targeted CAR-T cell therapy against BCMA and CD19, compared with standard treatment regimens in people with relapsed refractory multiple myeloma RRMM. This Phase III open-label, randomized global trial aims to compare the effectiveness and safety of AZD0120 against four standard regimens DKd daratumumab, carfilzomib, dexamethasone, DPd daratumumab, pomalidomide, dexamethasone, PVd pomalidomide, bortezomib, dexamethasone, and Kd carfilzomib, dexamethasone. Participants will be randomly assigned to receive either AZD0120 or one of the four standard regimens chosen by their investigator. AZD0120 is a biological CAR-T cell therapy, while the standard regimens involve combinations of drugs administered according to routine care. The study evaluates treatment effectiveness over several years, including progression-free survival and minimal residual disease negativity. During the trial, participants will undergo regular assessments including laboratory tests and clinical evaluations to monitor disease status and treatment response. Key outcomes include progression-free survival and minimal residual disease negativity rates. Safety and effectiveness will be monitored over multiple years. The total study duration extends up to 5 years, with participants followed for outcomes such as overall survival and response rates.

Age: 18Years +All GendersPhase 3
143 locations
P

Actively Recruiting

Researchers are evaluating the drug efruxifermin EFX in adults with compensated cirrhosis caused by NASH Nonalcoholic Steatohepatitis or MASH Metabolic Dysfunction-Associated Steatohepatitis. This phase 3, randomized, double-blind, placebo-controlled study aims to assess the safety and efficacy of EFX in slowing disease progression and improving liver health over several years. Participants will be randomly assigned to receive either EFX 50 mg or a placebo, both given by subcutaneous injection. The study includes two cohorts one with biopsy-proven compensated cirrhosis and metabolic features, and another diagnosed either by biopsy or non-invasive methods. Treatment and follow-up will continue for up to five years to monitor outcomes. Throughout the study, participants will undergo regular assessments including liver fibrosis markers, liver injury markers, lipoproteins, insulin sensitivity, glycemic control, and body weight changes. Safety will be closely monitored through laboratory tests, ECGs, ultrasounds, and vital signs. The primary outcome measures include time to significant clinical events like disease progression or liver decompensation and improvements in fibrosis and steatohepatitis, with follow-up extending up to five years.

Age: 18Years - 80YearsAll GendersPhase 3
345 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of efruxifermin EFX in adults with non-cirrhotic nonalcoholic steatohepatitis NASH or metabolic dysfunction-associated steatohepatitis MASH who have moderate to advanced liver fibrosis stage 2 or 3. This Phase 3, multi-center study randomly assigns participants to different treatment groups and compares EFX with a placebo to see its impact on liver health and related clinical outcomes. Participants are divided into two groups one with about 750 subjects having confirmed NASHMASH and fibrosis stage 2 or 3, and another with about 900 subjects with fibrosis stage 3 regardless of their NAFLD activity score. They receive either 28 mg or 50 mg of EFX or a matching placebo through weekly injections under the skin. The study includes a screening period up to 12 weeks, a 52-week treatment phase for the first group, a 96-week phase for the second group, and an extended follow-up period lasting up to around 240 weeks, plus a follow-up visit about a month after the last dose. During the study, participants undergo liver biopsies, blood tests, imaging scans like FibroScan, and assessments of liver fibrosis markers and metabolism-related measures. Researchers monitor changes in liver tissue, liver function tests, cholesterol, blood sugar control, body weight, and safety indicators over time. Even if participants stop the study drug early, they may continue with scheduled assessments to support long-term evaluation of treatment effects and safety throughout the study duration.

Age: 18Years - 80YearsAll GendersPhase 3
359 locations

1-10 of 105

1